Functional analysis of clinical BARD1 germline variants
Molecular Case Studies · 2019-08 · 5 (4) · a004093
DOI: 10.1101/mcs.a004093 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 01.08.2019. Verfasst von Ming Ren Toh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Duke-NUS Medical School, Singapore, 169857, Singapore. Hauptthemen laut MEDLINE: Breast Neoplasms, Colorectal Neoplasms, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Germline pathogenic variants in BRCA1/2 account for one-third of familial breast cancers. The majority of BRCA1 function requires heterodimerization with BARD1. In contrast to BRCA1 , BARD1 is a low-penetrance gene with an unclear clinical relevance, partly because of limited functional evidence. Using patient-derived lymphoblastoid cells, we functionally characterized two pathogenic variants (c.1833dupT, c.2099delG) and three variants of uncertain significance (VUSs) (c.73G>C, c.1217G>A, c.1918C>A). Three of these patients had breast cancers, whereas the remaining had colorectal cancers ( n = 3). Both patients with pathogenic variants (c.1833dupT, c.2099delG) developed breast cancers with aggressive disease phenotypes such as triple-negative breast cancer and high cancer grades. As BARD1 encompasses multiple functional domains, including those of apoptosis and homologous recombination repair, we hypothesized that the function being impaired would correspond with the domain where the variant was located. Variants c.1918C>A, c.1833dupT, c.1217G>A, and c.2099delG, located within and proximal to apoptotic domains of ankyrin and BRCT, were associated with impaired apoptosis. Conversely, apoptosis function was preserved in c.73G>C, which was distant from the ankyrin domain. All variants displayed normal BRCA1 heterodimerization and RAD51 colocalization, consistent with their location being distal to BRCA1—and RAD51-binding domains. In view of deficient apoptosis, VUSs (c.1217G>A and c.1918C>A) may be pathogenic or likely pathogenic variants. In summary, functional analysis of BARD1 VUSs requires a combination of assays and, more importantly, the use of appropriate functional assays with consideration to the variant's location.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke-NUS Medical School, Singapore, 169857, Singapore.
- Division of Medical Oncology, National Cancer Center, Singapore, 169610, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 639798, Singapore.
- Institute of Molecular and Cellular Biology, Agency for Science, Technology and Research, Singapore, 138673, Singapore.
Zitieren
APA
Toh, M. R., Chong, S. T., Chan, S. H., Low, C. E., Ishak, N. D. B., Lim, J. Q., Courtney, E., & Ngeow, J. (2019). Functional analysis of clinical BARD1 germline variants. Molecular Case Studies, 5(4), a004093. https://doi.org/10.1101/mcs.a004093
Vancouver
Toh MR, Chong ST, Chan SH, Low CE, Ishak NDB, Lim JQ, et al. Functional analysis of clinical BARD1 germline variants. Molecular Case Studies. 2019;5(4):a004093. doi:10.1101/mcs.a004093
BibTeX
@article{Toh2019,
author = {Toh, Ming Ren and Chong, Siao Ting and Chan, Sock Hoai and Low, Chen Ee and Ishak, Nur Diana Binte and Lim, Jing Quan and Courtney, Eliza and Ngeow, Joanne},
title = {Functional analysis of clinical BARD1 germline variants},
journal = {Molecular Case Studies},
year = {2019},
volume = {5},
number = {4},
pages = {a004093},
doi = {10.1101/mcs.a004093}
}
EUVIMED